Zhejiang Yatai Pharmaceutical Co., Ltd.

Equities

002370

CNE100000MM5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
3.13 CNY -1.57% Intraday chart for Zhejiang Yatai Pharmaceutical Co., Ltd. +5.39% -27.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Court Orders Bankruptcy Liquidation of Yatai Pharma Unit MT
Yatai Pharma Unit Creditor Seeks Bankruptcy Liquidation MT
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments CI
Yatai Pharmaceutical's Shareholder Plans to Sell 7.27% Stake in the Company CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. signed a mediation agreement to acquire the remaining 49% stake in Wuhan Optics Valley Yatai Pharmaceutical Co., Ltd. from Hubei Science & Technology Investment Group Corporation Limited. CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Omits Final Cash Dividend for 2019 CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Chart Zhejiang Yatai Pharmaceutical Co., Ltd.
More charts
Zhejiang Yatai Pharmaceutical Co., Ltd. is a China-based company engaged in the manufacture and distribution of drugs. The Company's main business consists of the research, development, production and sales of chemical agents, chemical raw materials and diagnostic reagents, as well as the provision of pharmaceutical research and development outsourcing (CRO) services. The Company’s chemical agents are classified as antibiotics and non-antibiotic drugs. Along with its subsidiaries, the Company provides preclinical research services, clinical research services and other advisory services. The Company distributes its products primarily in domestic markets and overseas markets.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002370 Stock
  4. News Zhejiang Yatai Pharmaceutical Co., Ltd.
  5. Court Orders Bankruptcy Liquidation of Yatai Pharma Unit